DNA-binding protein

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Retrieved on: 
Thursday, March 7, 2024
Health, Infectious Diseases, Health Technology, Research, Science, Pharmaceutical, Biotechnology, DNA sequencing, Therapy, Innovation, Doctor of Philosophy, Intelligence, Next Generation, HIMSS, Synthetic biology, Language, Silicon, Drug discovery, Entrepreneurship, Conference, Protein engineering, Natural language processing, Pharmacy, LLM, DNA-binding protein, InterSystems, Medicine, Fruit, Protein, Gene, Knowledge, Biology, Artificial intelligence, Natural language, NLP

The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.

Key Points: 
  • The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.
  • Central to the success of BioStrand's Foundation AI Model is its utilization of its patented HYFT technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere.
  • The Advanced Foundation AI model employs a distinctive approach known as "LLM stacking" to intelligently combine different LLMs, with the HYFTs linked to specific features found in various LLMs.
  • Our presentation will focus on introducing our groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

The Rainwater Charitable Foundation Announces 2024 Rainwater Prize Winners, Dr. Virginia Man-Yee Lee and Dr. Cristian Lasagna-Reeves, for Ongoing Contributions to Scientific Understanding of Tau in the Brain

Retrieved on: 
Thursday, February 15, 2024
Yee, DNA-binding protein, Tauopathy, BSN, ALS, Research, Dementia, TAR, Nature Neuroscience, PSP, Rain, Pathology, Alpha-synuclein, Neurodegenerative disease, Conference, Frontotemporal dementia, University, Medical laboratory, Drug discovery, Innovation, Associate, Movement, Biology, Brain, Pharmaceutical industry

FORT WORTH, Texas, Feb. 15, 2024 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative research that enables field-advancing programs, resources and breakthrough solutions for primary tauopathies, today announced Virginia Man-Yee Lee, Ph.D., University of Pennsylvania Perelman School of Medicine, will be awarded the 2024 Outstanding Innovation in Neurodegenerative Disease Research Prize of $400,000, and Cristian Lasagna-Reeves, Ph.D., M.S., Indiana University School of Medicine will be awarded the Rainwater Prize for Innovative Early-Career Scientist of $200,000. The prizes will be presented during the Tau2024 Global Conference on March 25-26, 2024, in Washington, D.C.

Key Points: 
  • The Rainwater Prize Program , now in its fifth year, aims to highlight and support scientific progress toward addressing critical gaps for neurodegenerative diseases associated with the accumulation of the tau protein in the brain.
  • Currently, Dr. Lasagna-Reeves' lab focuses on understanding the role of tau in Alzheimer's disease and related dementias.
  • Dr. Lasagna-Reeves winning this year's Early-Career Prize recognizes the scientific discoveries that could lead to a potential new therapeutic approach for tauopathies.
  • We're proud to support their research and provide resources that may contribute to potential future breakthroughs in our understanding of tau."

Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline

Retrieved on: 
Wednesday, February 14, 2024
Leptin, PD, Metabolism, Toxicity, Body composition, Ciprofloxacin, Clinical Pharmacokinetics, Water, LBW, Perfusion, LBM, Canadian International Council, AUC, PLOS One, Bariatric surgery, Clopidogrel, CYP, Breast, Health, DNA-binding protein, BMC Public Health, Pharmacology, BMI, CRP, Pharmaceutical Research (journal), Organ, Draft, Guideline, Bypass surgery, WHO, Ageing, INT, Pharmacokinetics, Liver, Bioavailability, Chronic liver disease, Human, Incidence, Committee, Absorption, TBW, Cardiovascular disease, Anatomy, CYP2C19, PBPK, Cmax, Factorization of polynomials, European, Lancet, CHMP, Journal, NASH, Pharmacotherapy, Adipose tissue, Non-alcoholic fatty liver disease, Journal of Clinical Investigation, Medication package insert, Overweight, NPS MedicineWise, Permeability, Benzodiazepine, Meta-analysis, Liver disease, Half-life, Acetylcholine, Ciclosporin, AAG, Kinetics, Midazolam, Kidney, Safety, Biomarker, Clinical Pharmacology & Therapeutics, Peptide, Classification, Hypertension, Metabolic syndrome, Acute coronary syndrome, Insulin resistance, Fatty liver disease, CYP2E1, Lithium, Body mass index, Reproduction, EMA, IBW, Injection, Anker, NCA, Enzyme, Inflammation, Cancer, Weight loss, Gastrointestinal tract, Cardiac output, Public health, Adipokine, CYP2C9, E pluribus unum, Physiology, Agency, Risk, Steroid, Lymph, CYP2D6, BSA, GI, Cytokine, Systematic review, Vaccine

Reflection paper on investigations of pharmacokinetics in

Key Points: 
    • Reflection paper on investigations of pharmacokinetics in
      the obese population
      Table of contents
      1.
    • References .............................................................................................. 9

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 2/12

      1.

    • This is considered
      a shortcoming that is potentially compounded by obese patients often being poorly represented in
      clinical studies.
    • The specific aims of this reflection paper are to:
      ?

      describe how the effects of obesity can be investigated during clinical medicinal product
      development.

    • ?

      provide recommendations on when investigations of the effect of obesity on the PK of a
      medicinal product should be particularly considered.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 3/12

      ?

      discuss how to reflect PK (and/or PK/PD) findings in weight/weight-based dosing
      recommendations.

    • Absorption
      Reduced rate of absorption linked to locally reduced blood flow (8) is reported for the subcutaneous
      and transdermal routes in obese subjects.
    • Distribution
      The distribution of medicinal products is driven by body composition, regional blood flow and binding to
      tissue and plasma proteins.
    • Obese subjects have a larger absolute lean body weight (LBW) as well as fat mass.
    • The physicochemical properties of a medicinal product (lipophilicity, polarity, molecular size, and
      degree of ionization) influence its distribution in the body.
    • In BMI class III obese
      subjects, the blood flow per gram of fat is significantly lower than that observed in class I obese or
      lean subjects (4).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 4/12

      An increased amount of alpha-1-acid-glycoprotein (AAG), linked to a chronic inflammatory state, is
      reported in obese individuals.

    • Fatty infiltrations are present in the liver for 90% of obese subjects, with the extent of the infiltrations
      being proportional to the degree of obesity.
    • In some cases, in particular for CYP3A4 metabolized medicinal products,
      bodyweight normalized clearance can be lower in obese patients (23).
    • Based on presently available data, it has been suggested that uptake transporters

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 5/12

      are downregulated while efflux transporters may be upregulated (31).

    • Platelet hyper-reactivity is also observed,
      which can impair the response to anti-platelet medicinal products in obese patients (42, 43).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 6/12

      3.

      the medicinal product properties and scientific literature indicate that obesity may lead to a
      marked effect on elimination and/or distribution or on the PK/PD relationship.

    • These
      models may aid in extrapolating the known efficacy and safety in the non-obese population to the
      obese population.
    • The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients
      Before and One Year After Bariatric Surgery.
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 11/12

      41.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 12/12

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

Retrieved on: 
Wednesday, December 20, 2023
Biology, Partnership, Drug discovery, DNA-binding protein, Matchmaker, Biochemistry, Library, Proteome, REAL, Machine learning, Fine chemical

“We believe combining one of the largest chemical libraries with our protein-ligand predictor tool, MatchMaker, will unlock the ability to generate more powerful compound libraries for drug discovery purposes.”

Key Points: 
  • “We believe combining one of the largest chemical libraries with our protein-ligand predictor tool, MatchMaker, will unlock the ability to generate more powerful compound libraries for drug discovery purposes.”
    “Chemical space is limitless,” said Andrey Tolmachov.
  • From there, Recursion will utilize MatchMaker’s predicted protein-ligand interactions for Enamine REAL Space containing 36B compounds to design compound libraries enriched for molecules that are likely to bind to biological targets.
  • Enamine may offer the resulting libraries to customers for purchase and will co-brand any libraries under both the Enamine and MatchMaker trademarks.
  • Furthermore, Recursion will receive preferential pricing on any enriched screening libraries made available to Enamine customers as part of the collaboration.

Rockland Launches Novel Analytical Tools to Assess Drug Delivery: Revolutionizing Oligonucleotide Therapeutic Development

Retrieved on: 
Tuesday, October 17, 2023
Triage, IHC, Drug development, RNA, Cell, DNA-binding protein, ELISA, In situ hybridization, ADMET, Panel, Absorption, Metabolism, ISH, Collection, MOE, Toxicology, PS, ASO, Small RNA, Ome, Tissue, Immunohistochemistry, Messenger, Serum, Vaccine, Fine chemical

LIMERICK, Pa., Oct. 17, 2023 /PRNewswire/ -- Rockland is a leading USA-based life science company, developing analytical tools that assist in the collection of pharmacodynamic, pharmacokinetic, and toxicology data critical for satisfying regulatory requirements for biological drugs, cell and gene therapies, and RNA therapeutic drugs (e.g., ASO, siRNA, mRNA). To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.

Key Points: 
  • To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.
  • Traditionally, ISH-type assays have been the mainstay method of detecting and localizing oligonucleotides in cells and tissues for nucleic acid therapy development.
  • Introducing the ModDetect™ Phosphorothioate (PS) Panel, an immunoassay-based alternative that provides robust detection of oligonucleotide therapeutic drug delivery and analysis, facilitating the collection of ADMET analytical data for regulatory approval.
  • ModDetect ™ is a growing suite of analytical tools generated against different types of nucleic acid chemical modifications.

Revolutionize Preclinical Drug Candidate Discovery with Syntekabio

Retrieved on: 
Saturday, June 3, 2023
Tradition, DNA-binding protein, Drug development, CLOUD, STB, Pharmacokinetics, Toxicity, Drug, KOSDAQ, Protein, Metabolism, MD, Permeability, Drug discovery, Artificial intelligence, Environment, Pharmaceutical industry, Medical imaging

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the launch of its cost-effective AI-based total solution service for finding new drug candidates.

Key Points: 
  • Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the launch of its cost-effective AI-based total solution service for finding new drug candidates.
  • This process drastically shortens the period before pre-clinical trials to two years from what averages to be up to seven years in traditional drug development.
  • Furthermore, Traditional new drug development can cost more than 10 million dollars until pre-clinical trials.
  • Syntekabio’s new drug discovery solutions will be unveiled at the 2023 BIO International Convention in Boston, June 5-8 at booth #2785.

Eight Student Teams Named National Winners of 31st Annual ExploraVision Challenge

Retrieved on: 
Tuesday, May 2, 2023
Family, Engineering, Technology, Consumer, Teens, Manufacturing, Parenting, Children, Public Relations, Investor Relations, Communications, Nanotechnology, Alternative Energy, Energy, Foundation, Science, Primary, Secondary, Education, Philanthropy, Forest Products, Agriculture, Natural Resources, Research, ER, ExploraVision, DNA-binding protein, Violence, Friends, Hearing loss, NSF, Parent, Mycelium, Clothing, Fire, Mentorship, Fungus, Government, Creativity, NSTA, Student, Hospital, Perchlorate, NASA, STEM, Bill Nye the Science Guy, Ecosystem, Bacteria, Imagination, Next Generation Science Standards, NIH, Mars, Toshiba

Toshiba and the NSTA today announced eight national winners of the 31st annual Toshiba/NSTA ExploraVision challenge, the world’s largest K-12 science competition.

Key Points: 
  • Toshiba and the NSTA today announced eight national winners of the 31st annual Toshiba/NSTA ExploraVision challenge, the world’s largest K-12 science competition.
  • The Toshiba/NSTA ExploraVision challenge is designed to inspire students to develop the skills emphasized in the Next Generation Science Standards, including problem-solving, critical-thinking and collaboration skills.
  • The eight national winning teams are comprised of a first-place winner and second-place winner from four groups based on grade level.
  • Follow ExploraVision on Twitter at https://twitter.com/ToshibaAmerica or join the ExploraVision Facebook Page at https://www.facebook.com/ToshibaAmerica .

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

Retrieved on: 
Wednesday, April 19, 2023
ISLAND, VRE, Clostridioides difficile infection, DNA, DNA-binding protein, University, IV, Flagellum, Public, IIIC, MRSA, Infection, Genetically modified bacteria, Houston Community College, Solubility, DRSP, Movement, Congress, Professor, ECCMID, Vancomycin, European, Metronidazole, University of Houston, Fidaxomicin, Susceptibility, Poster, Principal, Pharmacology, Recurrence, Virulence, Safety, Microbiology, Vaccine, Pharmacy

C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.

Key Points: 
  • C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.
  • To study anti-virulence effect, our group investigated an under-studied virulence property of C difficile, namely, flagellar movement of the organism.
  • All of these positive and unexpected findings reflect the unique mode of action in inhibiting DNA pol IIIC and support the continued development of ibezapolstat to treat C. difficile infection."
  • The poster and presentation are available on the Company's website www.acurxpharma.com.

Amber Salzman, Ph.D., CEO of Epic Bio, Recognized by Endpoints News as One of the Most Influential Women in Biopharma R&D

Retrieved on: 
Wednesday, December 7, 2022
Research, Women, Genetics, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Gene expression, Biotechnology, Therapy, AAV, Culture, A1AD, GEMS, Woman, DCAS, Amber, Stop, Patient, Epic, DNA, Research, Disease, ALD, News, FSHD, Horizons Ventures, CRISPR, DNA-binding protein, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Vaccine

She will additionally be featured in Endpoints Women in Biopharma 2022 special report.

Key Points: 
  • She will additionally be featured in Endpoints Women in Biopharma 2022 special report.
  • I am honored to be selected as one of Endpoints influential women blazing trails in biopharma, but my success would not have been possible without the Epic Bio team and the many people who supported and mentored me through my journey.
  • In addition, we have built a culture of diversity and inclusivity at Epic that enhances our ability to innovate.
  • Each year, Endpoints News selects 20 women in biotech to be honored as trailblazers in biopharma R&D.

Epic Bio to Participate in the BMO Virtual Spotlight Series

Retrieved on: 
Tuesday, November 15, 2022
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, AAV, GEMS, Gene expression, Biotechnology, Engineering, Bio, DNA, DCAS, Research, Horizons Ventures, CRISPR, DNA-binding protein, FSHD, A1AD, Facioscapulohumeral muscular dystrophy, Vaccine

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.
  • Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are scheduled to participate in a fireside chat from 11:00 11:25 am ET.
  • Epic Bio is a leading epigenome engineering company leveraging the power of CRISPR without cutting DNA.
  • Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications.